Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bayer buys herbal firm; NBTY notes bright spots, hires international leader; Neptune prepares to rebuild; P&G suit targets CAO’s tooth whiteners; CSPI supports restricting St. John’s wort; Coppertone schools parents; Hillary Clinton will speak at NACDS Total Store Expo.

You may also be interested in...



P&G Crest Whitestrips Patents Stand Up To ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening-strip firms infringed three of its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

P&G Crest Whitestrips Patents Repel ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening strip firms infringed three off its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

P&G Crest Whitestrips Patents Repel ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening strip firms infringed three off its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel